Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer

BACKGROUND: Lapatinib plus capecitabine is an effective treatment option for trastuzumab-refractory HER2-positive metastatic breast cancer. We have investigated the correlation between quantitative measures of HER2, p95HER2, and HER3 and treatment outcomes using lapatinib and capecitabine. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Sae-Won, Cha, Yongjun, Paquet, Agnes, Huang, Weidong, Weidler, Jodi, Lie, Yolanda, Sherwood, Thomas, Bates, Michael, Haddad, Mojgan, Park, In Hae, Oh, Do-Youn, Lee, Keun Seok, Im, Seock-Ah, Bang, Yung-Jue, Ro, Jungsil, Kim, Tae-You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407213/
https://www.ncbi.nlm.nih.gov/pubmed/22848366
http://dx.doi.org/10.1371/journal.pone.0039943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407213/
https://www.ncbi.nlm.nih.gov/pubmed/22848366
http://dx.doi.org/10.1371/journal.pone.0039943

Ejemplares similares